Discovery and validation of methylation markers for endometrial cancer

International Journal of Cancer

Volumn 135, Issue 8, 2014, Pages 1860-1868

  Wentzensen, Nicolas ^a   Bakkum Gamez, Jamie N ^b   Killian, J Keith ^a   Sampson, Joshua ^a   Guido, Richard ^c   Glass, Andrew ^d   Adams, Lisa ^a   Luhn, Patricia ^a   Brinton, Louise A ^a   Rush, Brenda ^d   D'Ambrosio, Lori ^c   Gunja, Munira ^a   Yang, Hannah P ^a   Garcia Closas, Montserrat ^e   Lacey Jr , James V ^f   Lissowska, Jolanta ^g   Podratz, Karl ^b   Meltzer, Paul ^a   Shridhar, Viji ^b   Sherman, Mark E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d DIVISION OF RESEARCH   (United States)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f Department of Medical Oncology and Experimental Therapeutics   (United States)

^g INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

biomarker; early detection; endometrial cancer; methylation; vaginal bleeding

Indexed keywords

NUCLEAR FACTOR Y; TRANSCRIPTION FACTOR SOX1;

ADCYAP1 GENE; ARTICLE; ASCL2 GENE; CONTROLLED STUDY; CPG ISLAND; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; EARLY DIAGNOSIS; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE; GENETIC ANALYSIS; HS3ST2 GENE; HTR1B GENE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; MME GENE; MOLECULAR PROBE; NPY GENE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYROSEQUENCING; SOX1 GENE; VAGINA BLEEDING; VALIDATION PROCESS;

BIOMARKER; EARLY DETECTION; ENDOMETRIAL CANCER; METHYLATION; VAGINAL BLEEDING;

ADENOCARCINOMA; CASE-CONTROL STUDIES; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENES, NEOPLASM; HUMANS; ROC CURVE; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84905686310     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28843     Document Type: Article

References (37)

1. American Cancer Society. Cancer Facts and Figures 2012. 2012. http://www.cancer.org/research/cancerfactsstatistics/index.
2. Wright JD, Barrena Medel NI, et al. Contemporary management of endometrial cancer. Lancet 2012; 379: 1352-60.
3. Kosary CL,. Cancer of the Corpus Uteri. In:, Gloeckler Ries LA, Young JL, Keel GE, Eisner MP, Lin YD, Horner MD, eds. SEER survival monograph: cancer survival among adults, 2007. 123-32. http://seer.cancer.gov/archive/ publications/survival/seer-survival-mono-lowres.pdf.
4. Lacey JV, Jr, Ioffe OB, Ronnett BM, et al. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. Br J Cancer 2008; 98: 45-53.
5. Lacey JV, Jr, Sherman ME, Rush BB, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010; 28: 788-92.
6. van Hanegem N, Breijer MC, Khan KS, et al. Diagnostic evaluation of the endometrium in postmenopausal bleeding: an evidence-based approach. Maturitas 2011; 68: 155-64.
7. van HN, Breijer MC, Opmeer BC, et al. Prediction models in women with postmenopausal bleeding: a systematic review. Womens Health (Lond Engl) 2012; 8: 251-62.
8. Sherman ME, Ronnett BM, Ioffe OB, et al. Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification. Int J Gynecol Pathol 2008; 27: 318-25.
9. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106: 812-9.
10. Trimble CL, Method M, Leitao M, et al. Management of endometrial precancers. Obstet Gynecol 2012; 120: 1160-75.
11. Bach PB, Schrag D, Brawley OW, et al. Survival of blacks and whites after a cancer diagnosis. JAMA 2002; 287: 2106-13.
12. Gallicchio L, Harvey LA, Kjerulff KH,. Fear of cancer among women undergoing hysterectomy for benign conditions. Psychosom Med 2005; 67: 420-4.
13. Jiang SW, Li J, Podratz K, et al. Application of DNA methylation biomarkers for endometrial cancer management. Expert Rev Mol Diagn 2008; 8: 607-16.
14. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
15. Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013; 5: 167ra4.
16. Zhou XC, Dowdy SC, Podratz KC, et al. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol Oncol 2007; 107: 143-53.
17. Brinton LA, Sakoda LC, Lissowska J, et al. Reproductive risk factors for endometrial cancer among Polish women. Br J Cancer 2007; 96: 1450-6.
18. Kipp BR, Medeiros F, Campion MB, et al. Direct uterine sampling with the Tao brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia: a feasibility study. Cancer 2008; 114: 228-35.
19. Bibikova M, Fan JB,. GoldenGate assay for DNA methylation profiling. Methods Mol Biol 2009; 507: 149-63.
20. Killian JK, Bilke S, Davis S, et al. Large-scale profiling of archival lymph nodes reveals pervasive remodeling of the follicular lymphoma methylome. Cancer Res 2009; 69: 758-64.
21. Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125: 279-84.
22. Munoz JF, Rueda M,. New imputation methods for missing data using quantiles. J Comput Appl Math 2009; 232: 305-17.
23. Simon R, Lam A, Li MC, et al. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007; 3: 11-7.
24. Nieminen TT, Gylling A, Abdel-Rahman WM, et al. Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res 2009; 15: 5772-83.
25. Shivapurkar N, Sherman ME, Stastny V, et al. Evaluation of candidate methylation markers to detect cervical neoplasia. Gynecol Oncol 2007; 107: 549-53.
26. Takai D, Yagi Y, Wakazono K, et al. Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis. Oncogene 2001; 20: 7505-13.
27. Archer KJ, Mas VR, Maluf DG, et al. High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma. Mol Genet Genom 2010; 283: 341-9.
28. de Sousa E Melo, Colak S, Buikhuisen J, et al. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 2011; 9: 476-85.
29. Cohen JR, Resnick DZ, Niewiadomski P, et al. Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures. BMC Cancer 2010; 10: 676.
30. Zhang L, Bijker MS, Herzog H,. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol Ther 2011; 131: 91-113.
31. Zhang L, Nguyen AD, Lee IC, et al. NPY modulates PYY function in the regulation of energy balance and glucose homeostasis. Diabetes Obes Metab 2012; 14: 727-36.
32. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-78.
33. Torres ML, Weaver AL, Kumar S, et al. Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol 2012; 120: 998-1004.
34. Evans T, Sany O, Pearmain P, et al. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer 2011; 104: 1505-10.
35. Widschwendter A, Gattringer C, Ivarsson L, et al. Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res 2004; 10: 3396-400.
36. Wu HH, Harshbarger KE, Berner HW, et al. Endometrial brush biopsy (Tao brush). Histologic diagnosis of 200 cases with complementary cytology: an accurate sampling technique for the detection of endometrial abnormalities. Am J Clin Pathol 2000; 114: 412-8.
37. Wentzensen N, Wacholder S,. From differences in means between cases and controls to risk stratification: a business plan for biomarker development. Cancer Discov 2013; 3: 148-57.